A stock in the biotechnology and drugs complex whose insiders have bought up a decent amount of stock is Endoyte (ECYT), which is engaged in developing therapies for the treatment of cancer and inflammatory diseases. Insiders are spotting some deep value here since the stock is off by over 50% in 2011.
Endoyte has a market cap of $155.08 million and an enterprise value of -$14.82 million. Its estimated growth rate for the next quarter is 25.6%, and for next year it's pegged at 17.1%. This is an extremely cash-rich company, with a total cash position of $138.87 million and total debt of just $12.19 million. After you back out the debt, its total cash comes to $126.68 million.A director just bought 125,000 shares, or $420,000 worth of stock, at $3.36 per share. From a technical standpoint, ECYT is currently trading substantially below both its 50-day and 200-day moving averages, which is bearish. This stock recently gapped down huge from over $10 a share to under $4 a share. After that monster gap down that came on huge volume, ECYT went on to hit a low of $3.02. If you're bullish on ECYT, I would look to get long once it breaks out above some near-term overhead resistance at $3.28 on high volume. Look for volume that's tracking in close to or above its three-month average action of 439,886 shares. I would use a mental stop just below $3.10 or $3.02 a share, which are both near-term support zones. Another way to trade ECYT is to buy the stock once it starts to trade back above the gap down day high at $4.29 a share on huge volume. Once that trade triggers, then ECYT should bounce huge as it attempts to refill some of that massive gap down. Keep in mind that stocks with lots of gaps in their charts are risky, so that trade above the gap down day high is a better play since it will demonstrate more strength in this equity.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV